EDEN PRAIRIE, Minn., June 23, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the company will host an interactive, physician-led webinar to discuss treatment of fluid overload ...
Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don’t respond to diuretics MINNEAPOLIS, Feb. 06, 2024 (GLOBE ...
NEWTON, Mass. and SHEFAYIM, Israel, Dec. 8, 2025 /PRNewswire/ -- AQUAPASS, a medical technology company pioneering non-invasive fluid management solutions, has received marketing approval for the ...
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NUWE) (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is ...
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...
Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure. Last year, the drug developer noted that FDA feedback from a 2023 Type D ...
Ghent, Belgium, 2 February 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...
Ghent, Belgium, 28 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results